Scynexis(SCYX)
JERSEY CITY, NJBiotechnology
Focus: Scynexis is a public biotech company focused on small-molecule antifungal therapeutics for infectious diseases and respiratory indications. The company operates as a clinical-stage innovator with a concentrated pipeline targeting serious fungal infections.
Profile data last refreshed 18h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Scynexis
AI assessmentNot HiringNo open roles listed right now. Follow Scynexis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Scynexis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$4M
Pipeline & Clinical Trials
Non-interventional study
Vulvovaginal Candidiasis[14C]-Ibrexafungerp
Fungal InfectionClinical Trials (1)
Help build intelligence for Scynexis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.